ArticleThe Journal of investigative dermatology2022
Dual Targeting with EZH2 Inhibitor and STING Agonist to Treat Melanoma.
Article in The Journal of investigative dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 8 citations in OpenAlex.
- Cell-type specific activation of the cGAS-STING pathway in tumor immunotherapy: mechanisms and therapeutic implications.Journal of translational medicine · 2026Review
- EZH2 in Acral Lentiginous Melanoma: Molecular, Epigenetic, and Therapeutic Perspectives.Oncology research · 2026Review
- Epigenetic control of antigen presentation failure in osteosarcoma: from single-cell chromatin maps to therapeutic strategies.Frontiers in immunology · 2025Review
- Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The immunotherapy era has ushered in enormous promise for cancer, largely led by progress in melanoma management. However a significant fraction of melanoma patients suffers early progression or relapse due to treatment resistance. Immunologically cold tumors are often refractory to immunotherapies and are associated with a lack of interferon signalling and antigen presentation. In their new article, Xu et al. (2022) demonstrate that the epigenetic modifier enhancer of zeste homolog 2 (EZH2) regulates expression of the innate immune signalling factor STING and that dual targeting of EZH2 and STING induces interferon signalling, major histocompatibility complex expression and synergistically reduces tumor growth in a preclinical model. Strategies such as this stand to improve therapeutic opportunities for otherwise refractory tumor contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.